HOME Top Market Reports Active Pharmaceutical Ingredient (API) Market Trends, Competitive Landscape and Global Forecasts (2011-2016)

Active Pharmaceutical Ingredient (API) Market Trends, Competitive Landscape and Global Forecasts (2011-2016)

By: marketsandmarkets.com
Publishing Date: December 2011
Report Code: PH 1262

Discount on Reports  

  Speak to Analyst Enquiry Before Buying
Analyst Briefing  
purchase report
download pdf  request for customisation


The Development in the High Potency Active Pharmaceutical Ingredient (HPAPI) and Biogeneric drugs is boosting the growth of the Active Pharmaceutical Ingredient (API) market. There has been a paradigm shift in the use of innovative drugs to that of low-cost API drugs after the economic recession, thereby causing a positive impact on the overall growth of the API market. In order to keep abreast with this change, API manufacturers are applying various novel technologies to reduce the processing time in order to yield more production.

The report describes the API market according to types of:

  • API synthesis
  • Customers
  • Players

It also discusses about the API market in various geographies, such as, North America, Europe, and Asia.
The report also describes the HPAPI market according to the types of:

  • API synthesis
  • Customers
  • Players

The Active Pharmaceutical Ingredient (API) forms the most vital part of every formulated end product, and is an important part of the whole pharmaceutical industry. The overall API market was valued at $101.08 billion in 2010, and is expected to grow at a CAGR of 7.9% from 2011 to 2016.

There has been an increase in influence of API players from emerging economies such as India and China after the economic recession. The recession restricted the growth of Innovative sector in developed economies such as the U.S and Europe, as the Innovative sector requires huge investments. This has helped fuel the growth of Generics market in Asian countries such as India and China.

The API market is facing a period of unprecedented growth as market dynamics have undergone a major change with the expiration of patents pertaining to global blockbuster drugs in the U.S. The consequences of the economic crisis has hit the Innovative drugs market hard, with less budgets allocated by the major players for the R&D of Innovative drugs. This has led to drying up of pipelines for new drugs, and therefore the market for generic drugs is quickly growing. Thus, the patent expiry factor is slated to drive the API market for the coming years.

European countries such as the U.K., France, and Germany are promoting the use of Generics by providing incentives to the doctors for writing prescriptions relating to generic drugs and also to the pharmacists if they offer the generic equivalent of prescribed drugs. Thus, generic API market is expected to grow till the year 2016 as compared to the Innovative API Market.

The HPAPI market is driving the API market growth globally at a fast rate. As these compounds are extremely effective in the treatment of cancers, respiratory disorders, and hormonal imbalances, the HPAPIs market is mostly driven by the growth in the oncology therapeutics market worldwide. The global HPAPI market is valued at $8,900 million in 2011, growing at a CAGR of 8.3% till 2016.

The HPAPI compounds are highly effective due to the targeted therapy. Hence, its application for cancers is a major driver. The market of North America is the largest and accounts for major share; followed by Europe; but Asia is growing at a higher CAGR as compared to North America & Europe. The major players for the HPAPI market are SAFC, Novasep, Lonza, Boehringer Ingelheim, and Carbogen Amics.

Mergers and collaborations are the strategies that have been noticed across the API industry. Newer market entrants are causing threats to the existing small and medium manufactures, leading to high competition. To overcome these challenges, companies are now forming joint ventures for sharing the technology to manufacture API drugs. The key to survive in the market for SMEs is joint ventures.

TABLE OF CONTENTS    
   
1 INTRODUCTION  
  1.1 KEY TAKE-AWAYS  
  1.2 REPORT DESCRIPTION  
  1.3 MARKETS COVERED  
  1.4 STAKEHOLDERS  
  1.5 RESEARCH METHODOLOGY  
      1.5.1 MARKET SIZE  
      1.5.2 ASSUMPTIONS  
      1.5.3 RESEARCH METHODOLOGY FOR HPAPI MARKET  

2 SUMMARY  

3 MARKET OVERVIEW  
  3.1 INTRODUCTION  
  3.2 MARKET STRUCTURE  
      3.2.1 DRIVERS  
            3.2.1.1 Asia leading the Global API market participation  
            3.2.1.2 Major drugs approaching patent expiries: Spike in the growth of API Market  
            3.2.1.3 Government promoting generic drug usage  
      3.2.2 RESTRAINTS  
            3.2.2.1 Decline in the overall R&D expenditure affecting the pharmaceutical industry  
            3.2.2.2 Big pharmaceutical players shifting their focus to Generics: Leading to increase in market fragmentation  
      3.2.3 OPPORTUNITIES  
            3.2.3.1 Shifting focus to HPAPI  
            3.2.3.2 Investment into Biosimilars  
  3.3 TECHNOLOGY TRENDS  
      3.3.1 CONTINUOUS PROCESSING TECHNOLOGY  
      3.3.2 SEPARATION TECHNOLOGY  
            3.3.2.1 Fermentation process  
            3.3.2.2 Purification process  
            3.3.2.3 Filtration process  
            3.3.2.4 Drying process  
      3.3.3 MICRO REACTOR TECHNOLOGY  
      3.3.4 BENEFITS FROM MICRO REACTOR TECHNOLOGY & FLOW CHEMISTRY  
      3.3.5 GREEN CHEMISTRY MANUFACTURING  
  3.4 WINNING IMPERATIVES  
            3.4.1.1 Embarking on advanced technology  
            3.4.1.2 Joint ventures of API manufacturers.  
            3.4.1.3 Approvals of DMFs  
            3.4.1.4 Tracking of the off-patents  
  3.5 BURNING ISSUES  
            3.5.1.1 Lack of quality standards  
            3.5.1.2 Regulatory affairs  
            3.5.1.3 IP Protection to the Asian market  
            3.5.1.4 Product differentiation a major concern of API manufacturers.
  3.6 KEY MARKET DYNAMICS  
  3.7 MARKET ATTRACTIVESS  
      3.7.1 GLOBAL API MARKET  

4 API MARKET, BY TYPE OF SYNTHESIS  
  4.1 OVERVIEW  
  4.2 SUB-SEGMENTS OF API MARKET, BY TYPE OF SYNTHESIS  
      4.2.1 SYNTHETIC CHEMICALS API  
            4.2.1.1 Synthetic chemical APIs, by types  
                    4.2.1.1.1 Innovative  
                    4.2.1.1.2 Generic  
      4.2.2 BIOTECH API  
            4.2.2.1 By products  
                    4.2.2.1.1 Monoclonal antibodies  
                    4.2.2.1.2 Recombinant proteins  
                    4.2.2.1.3 Vaccines  
            4.2.2.2 By Customers  
                    4.2.2.2.1 Innovative  
                    4.2.2.2.2 Biogeneric/biosimilars  

5 API MARKET, BY PLAYERS  
  5.1 OVERVIEW  
  5.2 CAPTIVE API MARKET  
  5.3 MERCHANT API MARKET  
      5.3.1 MERCHANT API MARKET, BY TYPES  
            5.3.1.1 Innovative  
            5.3.1.2 Generic  

6 API MARKET, BY CUSTOMER BASE  
  6.1 OVERVIEW  
  6.2 SUB-SEGMENTS OF API MARKET, BY CUSTOMERS  
      6.2.1 GENERIC API  
      6.2.2 INNOVATIVE  

7 HPAPI MARKET  
  7.1 INTRODUCTION  
      7.1.1 HPAPI CLASSIFICATION AS PER SAFEBRIDGE CONSULTANTS  
      7.1.2 OVERVIEW: HPAPI GLOBAL MARKET  
      7.1.3 MANUFACTURING CAPABILITIES  
            7.1.3.1 Handling requirements  
            7.1.3.2 Personnel considerations  
            7.1.3.3 Plant & equipment  
            7.1.3.4 Technology  
  7.2 HPAPI MARKET, BY PRODUCTS  

8 GEOGRAPHICAL ANALYSIS  
  8.1 NORTH AMERICA  
      8.1.1 NORTH AMERICA API MARKET  
      8.1.2 NORTH AMERICA HPAPI MARKET  
      8.1.3 U.S. API MARKET  
      8.1.3.1 Regulatory approval  
      8.1.4 U.S. HPAPI MARKET  
      8.1.5 CANADA API MARKET  
            8.1.5.1 Regulatory approval  
      8.1.6 CANADA HPAPI MARKET  
  8.2 EUROPE  
      8.2.1 EUROPE API MARKET  
      8.2.2 EUROPE HPAPI MARKET  
      8.2.3 U.K. API MARKET  
            8.2.3.1 Regulatory approval  
      8.2.4 U.K. HPAPI MARKET  
      8.2.5 FRANCE API MARKET  
            8.2.5.1 Regulatory approval  
      8.2.6 FRANCE HPAPI MARKET  
      8.2.7 GERMANY API MARKET  
      8.2.7.1 Regulatory approval  
      8.2.8 GERMANY HPAPI MARKET  
      8.2.9 SPAIN API MARKET  
            8.2.9.1 Regulatory approval  
      8.2.10 SPAIN HPAPI MARKET  
      8.2.11 ITALY API MARKET  
            8.2.11.1 Regulatory approval  
      8.2.12 ITALY HPAPI MARKET  
      8.2.13 ROE API MARKET  
      8.2.14 ROE HPAPI MARKET  
  8.3 ASIA  
      8.3.1 ASIA API MARKET  
      8.3.2 ASIA HPAPI MARKET  
      8.3.3 INDIA API MARKET  
            8.3.3.1 Regulatory approval  
      8.3.4 INDIA HPAPI MARKET  
      8.3.5 JAPAN API MARKET  
            8.3.5.1 Regulatory approval  
      8.3.6 JAPAN HPAPI MARKET  
      8.3.7 SOUTH KOREA API MARKET  
            8.3.7.1 Regulatory approval  
      8.3.8 SOUTH KOREA HPAPI MARKET  
      8.3.9 CHINA API MARKET  
            8.3.9.1 Regulatory approval  
      8.3.10 CHINA HPAPI MARKET  
      8.3.11 ROA API MARKET  
      8.3.12 ROA HPAPI MARKET  

9 COMPETITIVE LANDSCAPE  
  9.1 INTRODUCTION  
  9.2 COMPETITIVE DEVELOPMENTS  

10 COMPANY PROFILES  
  10.1 ALBEMARLE CORPORATION  
      10.1.1 OVERVIEW  
      10.1.2 FINANCIALS  
      10.1.3 PRODUCTS & SERVICES  
      10.1.4 STRATEGY  
      10.1.5 DEVELOPMENTS  
  10.2 ASYMCHEM LABORATORIES INC  
      10.2.1 OVERVIEW  
      10.2.2 FINANCIALS  
      10.2.3 PRODUCTS & SERVICES  
      10.2.4 STRATEGY  
      10.2.5 DEVELOPMENTS  
  10.3 BOEHRINGER INGELHEIM GMBH  
      10.3.1 OVERVIEW  
      10.3.2 FINANCIALS  
      10.3.3 PRODUCTS & SERVICES  
      10.3.4 STRATEGY  
      10.3.5 DEVELOPMENTS  
  10.4 CAMBREX CORPORATION  
      10.4.1 OVERVIEW  
      10.4.2 FINANCIALS  
      10.4.3 PRODUCTS & SERVICES  
      10.4.4 STRATEGY  
      10.4.5 DEVELOPMENTS  
  10.5 COVIDIEN PLC  
      10.5.1 OVERVIEW  
      10.5.2 FINANCIALS  
      10.5.3 PRODUCTS & SERVICES  
      10.5.4 STRATEGY  
      10.5.5 DEVELOPMENT  
  10.6 DR. REDDY'S LABORATORIES LIMITED  
      10.6.1 OVERVIEW  
      10.6.2 FINANCIALS  
      10.6.3 PRODUCTS & SERVICES  
      10.6.4 STRATEGY  
      10.6.5 DEVELOPMENTS  
  10.7 BASF SE  
      10.7.1 OVERVIEW  
      10.7.2 FINANCIALS  
      10.7.3 PRODUCTS & SERVICES  
      10.7.4 STRATEGY  
      10.7.5 DEVELOPMENTS  
  10.8 HOSPIRA INC.  
      10.8.1 OVERVIEW  
      10.8.2 FINANCIALS  
      10.8.3 PRODUCTS & SERVICES  
      10.8.4 STRATEGY  
      10.8.5 DEVELOPMENTS  
  10.9 LONZA GROUP AG  
      10.9.1 OVERVIEW  
      10.9.2 FINANCIALS  
      10.9.3 PRODUCTS & SERVICES  
      10.9.4 STRATEGY  
      10.9.5 DEVELOPMENTS  
  10.10 MATRIX LABORATORIES LIMITED  
      10.10.1 OVERVIEW  
      10.10.2 FINANCIALS  
      10.10.3 PRODUCTS & SERVICES  
      10.10.4 STRATEGY  
      10.10.5 DEVELOPMENT  
  10.11 MYLAN INC  
      10.11.1 OVERVIEW  
      10.11.2 FINANCIALS  
      10.11.3 PRODUCTS & SERVICES  
      10.11.4 STRATEGY  
      10.11.5 DEVELOPMENTS  
  10.12 NOVARTIS INTERNATIONAL AG  
      10.12.1 OVERVIEW  
      10.12.2 FINANCIALS  
      10.12.3 PRODUCTS & SERVICES  
      10.12.4 STRATEGY  
      10.12.5 DEVELOPMENTS  
  10.13 GROUPE NOVASEP  
      10.13.1 OVERVIEW  
      10.13.2 FINANCIALS  
      10.13.3 PRODUCTS & SERVICES  
      10.13.4 STRATEGY  
      10.13.5 DEVELOPMENTS  
  10.14 PFIZER CENTRESOURCE  
      10.14.1 OVERVIEW  
      10.14.2 FINANCIALS  
      10.14.3 PRODUCTS & SERVICES  
      10.14.4 STRATEGY  
      10.14.5 DEVELOPMENTS  
  10.15 RANBAXY LABORATORIES LIMITED  
      10.15.1 OVERVIEW  
      10.15.2 FINANCIALS  
      10.15.3 PRODUCTS & SERVICES  
      10.15.4 STRATEGY  
      10.15.5 DEVELOPMENTS  
  10.16 ROYAL DSM N.V.  
      10.16.1 OVERVIEW  
      10.16.2 FINANCIALS  
      10.16.3 PRODUCTS & SERVICES  
      10.16.4 STRATEGY  
      10.16.5 DEVELOPMENTS  
  10.17 SIGMA-ALDRICH  
      10.17.1 OVERVIEW  
      10.17.2 FINANCIALS  
      10.17.3 PRODUCTS & SERVICES  
      10.17.4 STRATEGY  
      10.17.5 DEVELOPMENTS  
  10.18 TEVA PHARMACEUTICAL INDUSTRIES LIMITED  
      10.18.1 OVERVIEW  
      10.18.2 FINANCIALS  
      10.18.3 PRODUCTS & SERVICES  
      10.18.4 STRATEGY  
      10.18.5 DEVELOPMENTS  
  10.19 WATSON PHARMACEUTICALS INC  
      10.19.1 OVERVIEW  
      10.19.2 FINANCIALS  
      10.19.3 PRODUCTS & SERVICES  
      10.19.4 STRATEGY  
      10.19.5 DEVELOPMENTS  
  10.20 WUXI APPTEC CO. LTD.  
      10.20.1 OVERVIEW  
      10.20.2 FINANCIALS  
      10.20.3 PRODUCTS & SERVICES  
      10.20.4 STRATEGY  
      10.20.5 DEVELOPMENTS  
  10.21 ZHEJIANG HISUN PHARMACEUTICAL CO. LTD.  
      10.21.1 OVERVIEW  
      10.21.2 FINANCIALS  
      10.21.3 PRODUCTS & SERVICES  
      10.21.4 STRATEGY  
      10.21.5 DEVELOPMENTS   
    
   
LIST OF TABLES   
   
TABLE 1  DMF FILINGS WITH U.S. FDA, BY COUNTRY, 2005 – 2010 
TABLE 2  DRUGS GOING OFF-PATENT 
TABLE 3  DMF: FILING REQUIREMENTS & CHALLENGES 
TABLE 4  COMPANIES RANKED BY NUMBER OF ACTIVE DMFS FILED IN U.S. ACROSS ALL TYPES 
TABLE 5  GLOBAL API MARKET REVENUE BY TYPE OF SYNTHESIS, 2009 - 2016 ($BILLION) 
TABLE 6  SYNTHETIC API MARKET REVENUE,BY GEOGRAPHY, 2009 - 2016 ($BILLION) 
TABLE 7  NORTH AMERICA: SYNTHETIC API MARKET REVENUE, BY COUNTRY, 2009 - 2016 ($BILLION) 
TABLE 8  EUROPE: SYNTHETIC API MARKET REVENUE, BY COUNTRY,2009 – 2016 ($BILLION) 
TABLE 9  ASIA: SYNTHETIC API MARKET REVENUE, BY COUNTRY, 2009 – 2016 ($BILLION) 
TABLE 10 GLOBAL SYNTHETIC MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($BILLION)  
TABLE 11 BIOTECH API MARKET REVENUE, BY GEOGRAPHY, 2009 - 2016 ($BILLION)  
TABLE 12 NORTH AMERICA: BIOTECH API MARKET REVENUE, BY COUNTRY, 2009 - 2016 ($BILLION) 
TABLE 13 EUROPE: BIOTECH API MARKET REVENUE, BY COUNTRY, 2009 - 2016 ($BILLION)  
TABLE 14 ASIA: BIOTECH API MARKET REVENUE, BY COUNTRY, 2009 - 2016 ($BILLION)  
TABLE 15 GLOBAL BIOTECH API MARKET REVENUE, BY PRODUCTS, 2009 - 2016 ($BILLION)  
TABLE 16 GLOBAL BIOTECH API MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($BILLION)  
TABLE 17 GLOBAL API MARKET REVENUE, BY PLAYERS, 2009 – 2016 ($BILLION)  
TABLE 18 CAPTIVE MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($BILLION)  
TABLE 19 NORTH AMERICA: CAPTIVE API MARKET REVENUE, BY COUNTRY, 2009 – 2016 ($BILLION) 
TABLE 20 EUROPE: CAPTIVE API MARKET REVENUE, BY COUNTRY, 2009 – 2016 ($BILLION) 
TABLE 21 ASIA: CAPTIVE API MARKET REVENUE, BY COUNTRY, 2009 – 2016 ($BILLION)  
TABLE 22 MERCHANT MARKET REVENUE, BY GEOGRAPHY, 2009 - 2016 ($BILLION)  
TABLE 23 NORTH AMERICA: MERCHANT API MARKET REVENUE, BY COUNTRY, 2009 - 2016 ($BILLION) 
TABLE 24 EUROPE: MERCHANT API MARKET REVENUE, BY COUNTRY, 2009 - 2016 ($BILLION)  
TABLE 25 ASIA: MERCHANT API MARKET REVENUE, BY COUNTRY, 2009 - 2016 ($BILLION)  
TABLE 26 GLOBAL MERCHANT MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($BILLION)  
TABLE 27 GLOBAL API MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($BILLION)  
TABLE 28 TOP FIVE SELLING GENERICS  
TABLE 29 GENERIC API MARKET REVENUE, BY GEOGRAPHY, 2009 - 2016 ($BILLION)  
TABLE 30 NORTH AMERICA: GENERIC API MARKET REVENUE, BY COUNTRY, 2009 - 2016 ($BILLION) 
TABLE 31 EUROPE: GENERIC API MARKET REVENUE, BY COUNTRY, 2009 - 2016 ($BILLION)  
TABLE 32 ASIA: GENERIC API MARKET REVENUE, BY COUNTRY, 2009 - 2016 ($BILLION)  
TABLE 33 INNOVATIVE API MARKET REVENUE, BY GEOGRAPHY, 2009 - 2016 ($BILLION)  
TABLE 34 NORTH AMERICA: INNOVATIVE API MARKET REVENUE, BY COUNTRY, 2009 - 2016 ($BILLION) 
TABLE 35 EUROPE: INNOVATIVE API MARKET REVENUE, BY COUNTRY, 2009 - 2016 ($BILLION) 
TABLE 36 ASIA: INNOVATIVE API MARKET REVENUE, BY COUNTRY, 2009 - 2016 ($BILLION)  
TABLE 37 CATEGORIES OF HPAPI  
TABLE 38 POTENCY CLASSIFICATION SCHEME FOR HPAPI  
TABLE 39 HPAPI MARKET REVENUE, BY GEOGRAPHY, 2009 - 2016 ($MILLION)  
TABLE 40 GLOBAL HPAPI MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 - 2016 ($MILLION) 
TABLE 41 SYNTHETIC HPAPI MARKET REVENUE, BY GEOGRAPHY, 2009 - 2016 ($MILLION)  
TABLE 42 BIOTECH HPAPI MARKET REVENUE, BY GEOGRAPHY, 2009 - 2016 ($MILLION)  
TABLE 43 GLOBAL HPAPI MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($MILLION)  
TABLE 44 INNOVATIVE HPAPI MARKET REVENUE, BY GEOGRAPHY, 2009 - 2016 ($MILLION)  
TABLE 45 NORTH AMERICA: INNOVATIVE HPAPI MARKET REVENUE,  BY COUNTRY, 2009 - 2011 ($MILLION) 
TABLE 46 EUROPE: INNOVATIVE HPAPI MARKET REVENUE, BY COUNTRY, 2009 - 2011 ($MILLION) 
TABLE 47 ASIA: INNOVATIVE HPAPI MARKET REVENUE, BY COUNTRY, 2009 - 2011 (MILLION) 
TABLE 48 GENERIC HPAPI MARKET REVENUE, BY GEOGRAPHY, 2009 - 2016 ($MILLION)  
TABLE 49 NORTH AMERICA: GENERIC HPAPI MARKET REVENUE, BY COUNTRY, 2009 – 2016 ($MILLION) 
TABLE 50 EUROPE: GENERIC HPAPI MARKET REVENUE, BY COUNTRY, 2009 - 2016 ($MILLION) 
TABLE 51 ASIA: GENERIC HPAPI MARKET REVENUE, BY COUNTRY, 2009 - 2016 ($MILLION)  
TABLE 52 GLOBAL HPAPI MARKET REVENUE, BY PLAYERS, 2009 - 2016 ($MILLION)  
TABLE 53 CAPTIVE HPAPI MARKET REVENUE, BY GEOGRAPHY, 2009 - 2016 ($MILLION)  
TABLE 54 NORTH AMERICA: CAPTIVE HPAPI MARKET REVENUE, BY COUNTRY, 2009 - 2016 ($MILLION) 
TABLE 55 EUROPE: CAPTIVE HPAPI MARKET REVENUE, BY COUNTRY, 2009 - 2016 ($MILLION)  
TABLE 56 ASIA: CAPTIVE HPAPI MARKET REVENUE, BY COUNTRY, 2009 - 2016 ($MILLION)  
TABLE 57 MERCHANT HPAPI MARKET REVENUE, BY GEOGRAPHY, 2009 - 2016 ($MILLION)  
TABLE 58 NORTH AMERICA: MERCHANT HPAPI MARKET REVENUE, BY COUNTRY, 2009 - 2016 ($MILLION) 
TABLE 59 EUROPE: MERCHANT HPAPI MARKET REVENUE, BY COUNTRY, 2009 - 2016 ($MILLION) 
TABLE 60 ASIA: MERCHANT HPAPI MARKET REVENUE, BY COUNTRY, 2009 - 2016 ($MILLION)  
TABLE 61 NORTH AMERICA: API MARKET REVENUE,BY TYPE OF SYNTHESIS, 2009 - 2016 ($BILLION)  
TABLE 62 NORTH AMERICA: API MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($BILLION) 
TABLE 63 NORTH AMERICA: API MARKET REVENUE, BY PLAYERS, 2009 – 2016 ($BILLION)  
TABLE 64 NORTH AMERICA: HPAPI MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 – 2016 ($MILLION)  
TABLE 65   NORTH AMERICA: HPAPI MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($MILLION) 
TABLE 66 NORTH AMERICA: HPAPI MARKET REVENUE BY PLAYERS, 2009 - 2016 ($MILLION)  
TABLE 67 U.S: PREVALENCE OF DISEASES, 2010 - 2016 (THOUSANDS)  
TABLE 68 U.S: API MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 - 2016 ($BILLION)  
TABLE 69 U.S: API MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($BILLION)  
TABLE 70 U.S: API MARKET REVENUE, BY PLAYERS, 2009 - 2016 ($BILLION)  
TABLE 71 U.S: HPAPI MARKET REVENUE,BY TYPE OF SYNTHESIS, 2009 - 2016 ($MILLION)  
TABLE 72 U.S: HPAPI MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($MILLION)  
TABLE 73 U.S: HPAPI MARKET REVENUE, BY PLAYERS, 2009 - 2016 ($MILLION)  
TABLE 74 CANADA: PREVALENCE OF DISEASES, 2010 – 2016 (THOUSANDS)  
TABLE 75 CANADA: API MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 - 2016 ($BILLION)  
TABLE 76 CANADA: API MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($BILLION)  
TABLE 77 CANADA: API MARKET REVENUE, BY PLAYERS, 2009 - 2016 ($BILLION)  
TABLE 78 CANADA: HPAPI MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 - 2016 ($MILLION) 
TABLE 79 CANADA: HPAPI MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($MILLION)  
TABLE 80 CANADA: HPAPI MARKET REVENUE, BY PLAYERS, 2009 - 2016 ($MILLION)  
TABLE 81 EUROPE: API MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 - 2016 ($BILLION)  
TABLE 82 EUROPE: API MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($BILLION)  
TABLE 83 EUROPE: API MARKET REVENUE, BY PLAYERS, 2009 - 2016 ($BILLION)  
TABLE 84 EUROPE: HPAPI MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 - 2016 ($MILLION) 
TABLE 85 EUROPE: HPAPI MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($MILLION)  
TABLE 86 EUROPE: HPAPI MARKET REVENUE, BY PLAYERS, 2009 - 2016 ($MILLION)  
TABLE 87 U.K: PREVALENCE OF DISEASES, 2010 – 2016 (THOUSANDS)  
TABLE 88 U.K: API MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 - 2016 ($BILLION)  
TABLE 89 U.K: API MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($BILLION)  
TABLE 90 U.K: API MARKET REVENUE, BY PLAYERS,  2009 - 2016 ($BILLION)  
TABLE 91 U.K: HPAPI MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 - 2016 ($MILLION)  
TABLE 92 U.K: HPAPI MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($MILLION)  
TABLE 93 U.K: HPAPI MARKET REVENUE, BY PLAYERS, 2009 - 2016 ($MILLION)  
TABLE 94 FRANCE: PREVALENCE OF DISEASES,  2010 - 2016 (THOUSANDS)  
TABLE 95 FRANCE: API MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 - 2016 ($BILLION)  
TABLE 96 FRANCE: API MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($BILLION)  
TABLE 97 FRANCE: API MARKET REVENUE, BY PLAYERS, 2009 - 2016 ($BILLION)  
TABLE 98 FRANCE: HPAPI MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 - 2016, ($MILLION)  
TABLE 99 FRANCE: HPAPI MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($MILLION)  
TABLE 100 FRANCE: HPAPI MARKET REVENUE, BY PLAYERS, 2009 - 2016, ($MILLION)  
TABLE 101 GERMANY: PREVALENCE OF DISEASES, 2010 – 2016 (THOUSANDS)  
TABLE 102 GERMANY: API MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 - 2016 ($BILLION)  
TABLE 103 GERMANY: API MARKET REVENUE,BY CUSTOMERS, 2009 - 2016 ($BILLION)  
TABLE 104 GERMANY: API MARKET REVENUE, BY PLAYERS, 2009 - 2016 ($BILLION)  
TABLE 105 GERMANY: HPAPI MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 - 2016 ($MILLION) 
TABLE 106 GERMANY: HPAPI MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($MILLION)  
TABLE 107 GERMANY: HPAPI MARKET REVENUE, BY PLAYERS, 2009 - 2016 ($MILLION)  
TABLE 108 SPAIN: PREVALENCE OF DISEASES, 2010 – 2016 (THOUSANDS)  
TABLE 109 SPAIN: API MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 - 2016 ($BILLION)  
TABLE 110 SPAIN: API MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($BILLION)  
TABLE 111 SPAIN: API MARKET REVENUE, BY PLAYERS, 2009 - 2016 ($BILLION)  
TABLE 112 SPAIN: HPAPI MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 - 2016 ($MILLION)  
TABLE 113 SPAIN: HPAPI MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($MILLION)  
TABLE 114 SPAIN: HPAPI MARKET REVENUE, BY PLAYERS, 2009 - 2016 ($MILLION)  
TABLE 115   ITALY: PREVALENCE OF DISEASES, 2010 – 2016 (THOUSANDS)  
TABLE 116 ITALY: API MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 - 2016 ($BILLION)  
TABLE 117 ITALY: API MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($BILLION)  
TABLE 118 ITALY: API MARKET REVENUE, BY PLAYERS, 2009 - 2016 ($BILLION)  
TABLE 119 ITALY: HPAPI MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 - 2016 ($MILLION)  
TABLE 120 ITALY: HPAPI MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($MILLION)  
TABLE 121 ITALY: HPAPI MARKET REVENUE, BY PLAYERS, 2009 - 2016 ($MILLION)  
TABLE 122 ROE: API MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 - 2016 ($BILLION)  
TABLE 123 ROE: API MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($BILLION)  
TABLE 124 ROE: API MARKET REVENUE, BY PLAYERS, 2009 - 2016 ($BILLION)  
TABLE 125 ROE: HPAPI MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 - 2016 ($MILLION)  
TABLE 126 ROE: HPAPI MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($MILLION)  
TABLE 127 ROE: HPAPI MARKET REVENUE, BY PLAYERS, 2009 - 2016 ($MILLION)  
TABLE 128 ASIA: API MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 - 2016 ($BILLION)  
TABLE 129 ASIA: API MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($BILLION)  
TABLE 130 ASIA: API MARKET REVENUE, BY PLAYERS, 2009 - 2016 ($BILLION)  
TABLE 131 ASIA: HPAPI MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 - 2016 ($MILLION)  
TABLE 132 ASIA: HPAPI MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($MILLION)  
TABLE 133 ASIA: HPAPI MARKET REVENUE, BY PLAYERS, 2009 - 2016 ($MILLION)  
TABLE 134 INDIA: API MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 - 2016 ($BILLION)  
TABLE 135 INDIA: API MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($BILLION)  
TABLE 136 INDIA: API MARKET REVENUE, BY PLAYERS, 2009 - 2016 ($BILLION)  
TABLE 137 INDIA: HPAPI MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 - 2016 ($MILLION)  
TABLE 138 INDIA: HPAPI MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($MILLION)  
TABLE 139 INDIA: HPAPI MARKET REVENUE, BY PLAYERS, 2009 - 2016 ($MILLION)  
TABLE 140 INDIA: PREVALENCE OF DISEASES, 2010 - 2016 (THOUSANDS)  
TABLE 141 JAPAN: PREVALENCE OF DISEASES,  2010 – 2016 (THOUSANDS)  
TABLE 142 JAPAN: API MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 - 2016 ($BILLION)  
TABLE 143 JAPAN: API MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($BILLION)  
TABLE 144 JAPAN: API MARKET REVENUE, BY PLAYERS, 2009 - 2016 ($BILLION)  
TABLE 145 JAPAN: HPAPI MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 - 2016 ($MILLION)  
TABLE 146 JAPAN: HPAPI MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($MILLION)  
TABLE 147 JAPAN: HPAPI MARKET REVENUE, BY PLAYERS, 2009 - 2016 ($MILLION)  
TABLE 148 SOUTH KOREA: PREVALENCE OF DISEASES, 2010 - 2016 (THOUSANDS)  
TABLE 149 SOUTH KOREA: API MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 - 2016 ($BILLION) 
TABLE 150 SOUTH KOREA: API MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($BILLION)  
TABLE 151 SOUTH KOREA: API MARKET REVENUE, BY PLAYERS,2009 - 2016 ($BILLION)  
TABLE 152 SOUTH KOREA: HPAPI MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 - 2016 ($MILLION)  
TABLE 153 SOUTH KOREA: HPAPI MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($MILLION)  
TABLE 154 SOUTH KOREA: HPAPI MARKET REVENUE, BY PLAYERS, 2009 - 2016 ($MILLION)  
TABLE 155 CHINA: PREVALENCE OF DISEASES, 2010 - 2016 (THOUSANDS)  
TABLE 156 CHINA: API MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 - 2016 ($BILLION)  
TABLE 157 CHINA: API MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($BILLION)  
TABLE 158 CHINA: API MARKET REVENUE, BY PLAYERS, 2009 - 2016 ($BILLION)  
TABLE 159 CHINA: HPAPI MARKET REVENUE, BY TYPE OF SYNTHESIS, 2009 - 2016 ($MILLION)  
TABLE 160 CHINA: HPAPI MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($MILLION)  
TABLE 161 CHINA: HPAPI MARKET REVENUE, BY PLAYERS, 2009 - 2016 ($MILLION)  
TABLE 162 ROA: API MARKET REVENUE, BY TYPES OF SYNTHESIS, 2009 - 2016 ($BILLION)  
TABLE 163 ROA: API MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($BILLION)  
TABLE 164 ROA: API MARKET REVENUE, BY PLAYERS, 2009 - 2016 ($BILLION)  
TABLE 165 ROA: HPAPI MARKET REVENUE, BY TYPES OF SYNTHESIS, 2009 - 2016 ($MILLION)  
TABLE 166 ROA: HPAPI MARKET REVENUE, BY CUSTOMERS, 2009 - 2016 ($MILLION)  
TABLE 167 ROA: HPAPI MARKET REVENUE, BY PLAYERS, 2009 - 2016 ($MILLION)  
TABLE 168 ALBEMARLE CORPORATION: TOTAL REVENUE & R&D EXPENSES, 2008 - 2010 ($MILLION) 
TABLE 169 ALBEMARLE CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, 2008 - 2010 ($MILLION) 
TABLE 170 ALBEMARLE CORPORATION: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) 
TABLE 171 BOEHRINGER INGELHEIM GMBH TOTAL REVENUE AND R&D EXPENSES,2008 – 2010 ($MILLION)  
TABLE 172 BOEHRINGER INGELHEIM GMBH: TOTAL REVENUE, BY GEOGRAPHY, 2008 - 2010 ($MILLION) 
TABLE 173 BOEHRINGER INGELHEIM GMBH: TOTAL REVENUE, BY SEGMENTS, 2008 - 2010 ($MILLION) 
TABLE 174 CAMBREX CORPORATION: TOTAL REVENUES AND R&D EXPENSES, 2008 - 2010 ($MILLION) 
TABLE 175 CAMBREX CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, 2008 - 2010 ($MILLION) 
TABLE 176 CAMBREX CORPORATION: TOTAL REVENUE, BY SEGMENTS, 2008 - 2010 ($MILLION) 
TABLE 177   COVIDIEN PLC: TOTAL REVENUE AND R&D EXPENSES, 2008 –2010  ($MILLION)  
TABLE 178 COVIDIEN PLC: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)  
TABLE 179 COVIDIEN PLC: TOTAL REVENUE, BY SEGMENTS, 2008 - 2010 ($MILLION)  
TABLE 180 COVIDIEN PLC: TOTAL REVENUE OF ACTIVE PHARMACEUTICAL INGREDIENTS, 2008 - 2010 ($MILLION)  
TABLE 181 DR. REDDY'S LABORATORIES LTD: TOTAL REVENUE AND R&D EXPENSES, 2009 - 2011 ($MILLION)  
TABLE 182 DR.REDDY'S LABORATORIES LTD: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION) 
TABLE 183 DR. REDDY'S LABORATORIES LTD: TOTAL REVENUE, BY BUSINESS SEGMENTS, 2009 - 2011 ($MILLION) 
TABLE 184 BASF SE: TOTAL REVENUE AND R&D EXPENSES, 2008 - 2010 ($MILLION)  
TABLE 185 BASF SE: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)  
TABLE 186 BASF SE: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)  
TABLE 187 HOSPIRA INC: TOTAL REVENUE AND R&D EXPENSES 2008 – 2010 ($MILLION)  
TABLE 188 HOSPIRA INC: TOTAL REVENUE, BY GEOGRAPHY, 2008 - 2010 ($MILLION)  
TABLE 189 HOSPIRA INC: TOTAL REVENUE, BY SEGMENTS, 2008 - 2010 ($MILLION)  
TABLE 190 LONZA GROUP AG: TOTAL REVENUE AND R&D EXPENSES, 2008 - 2010 ($MILLION) 
TABLE 191 LONZA GROUP AG: TOTAL REVENUE, BY SEGMENTS, 2008 - 2010 ($MILLION)  
TABLE 192 LONZA GROUP AG: TOTAL REVENUE, BY GEOGRAPHY, 2008 –2010 ($MILLION)  
TABLE 193 MATRIX LABORATORIES LTD: TOTAL REVENUE AND R&D EXPENSES, 2008 - 2010 ($MILLION)  
TABLE 194 MATRIX LABORATORIES LTD: TOTAL REVENUE, BY SEGMENTS, 2008 - 2010 ($MILLION) 
TABLE 195 MATRIX LABORATORIES LTD: TOTAL REVENUE, BY PRODUCTS, 2008 - 2010 ($MILLION) 
TABLE 196 MATRIX LABORATORIES LTD: TOTAL REVENUE, BY GEOGRAPHY, 2008 - 2010 ($MILLION) 
TABLE 197 MYLAN INC.: TOTAL REVENUES & R&D EXPENSES, 2008 - 2010 ($MILLION)  
TABLE 198 MYLAN INC: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)  
TABLE 199 MYLAN INC: TOTAL REVENUE, BY SEGMENTS, 2008 - 2010 ($MILLION)  
TABLE 200 MYLAN INC: TOTAL REVENUE, BY PRODUCTS, 2008 - 2010 ($MILLION)  
TABLE 201 NOVARTIS INTERNATIONAL AG: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)  
TABLE 202 NOVARTIS INTERNATIONAL AG: TOTAL REVENUE, BY GEOGRAPHY, 2008 - 2010 ($MILLION) 
TABLE 203 NOVARTIS INTERNATIONAL AG: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) 
TABLE 204 PFIZER INC: TOTAL REVENUE & R&D EXPENSES, 2008 – 2010 ($MILLION)  
TABLE 205 PFIZER INC: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)  
TABLE 206 PFIZER INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)  
TABLE 207 RANBAXY LABORATORIES LIMITED: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)  
TABLE 208 RANBAXY LABORATORIES LIMITED: TOTAL REVENUE, BY GEOGRAPHY, 2008 - 2010 ($MILLION) 
TABLE 209 RANBAXY LABORATORIES LIMITED: TOTAL REVENUE, BY SEGMENTS, 2008 - 2010 ($MILLION) 
TABLE 210 ROYAL DSM N.V.: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)  
TABLE 211 SIGMA-ALDRICH: TOTAL REVENUE & R&D EXPENSES, 2008 – 2010 ($MILLION)  
TABLE 212 SIGMA-ALDRICH: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)  
TABLE 213 SIGMA-ALDRICH: TOTAL REVENUE, BY SEGMENTS, 2008 - 2010 ($MILLION)  
TABLE 214 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)  
TABLE 215 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) 
TABLE 216 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) 
TABLE 217 WATSON PHARMACEUTICALS INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)  
TABLE 218 WATSON PHARMACEUTICALS INC: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) 
TABLE 219 WATSON PHARMACEUTICALS INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) 
TABLE 220 WATSON PHARMACEUTICALS INC: TOTAL REVENUE, BY PRODUCTS, 2008 – 2010 ($MILLION) 
TABLE 221 WUXI APPTEC CO. LTD: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) 
TABLE 222 WUXI APPTEC CO. LTD: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) 
TABLE 223 WUXI APPTEC CO. LTD: TOTAL REVENUE, BY SEGMENTS, 2007 - 2009 ($MILLION) 
TABLE 224 ZHEJIANG HISUN PHARMACEUTICAL CO. LTD: TOTAL REVENUE AND R&D EXPENSES, 2008 - 2010 ($MILLION)  
TABLE 225 ZHEJIANG HISUN PHARMACEUTICAL CO. LTD: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)  
    
   
LIST OF FIGURES       
   
FIGURE 1 GLOBAL API MARKET REVENUE, 2009 – 2016 ($BILLION)  
FIGURE 2 GLOBAL API MARKET SEGMENTATION  
FIGURE 3 DMF FILING WITH THE U.S. FDA, BY COUNTRY 2005 - 2010  
FIGURE 4 FACTORS AFFECTING THE API MARKET  
FIGURE 5 GLOBAL API MARKET, BY COUNTRY,  2010  
FIGURE 6 GLOBAL API MARKET, BY COUNTRY, 2016  
FIGURE 7 GLOBAL HPAPI MARKET, BY COUNTRY, 2010  
FIGURE 8 GLOBAL HPAPI MARKET, BY COUNTRY, 2016  
FIGURE 9 API MARKET, BY TYPE OF SYNTHESIS  
FIGURE 10 API MARKET, BY TYPE OF PRODUCERS  
FIGURE 11 API MARKET, BY TYPE OF CUSTOMERS  
FIGURE 12 GLOBAL HPAPI MARKET REVENUE, 2009 – 2016 ($MILLION)  
FIGURE 13 MANUFACTURING CAPABILITIES OF HPAPI  
FIGURE 14 HPAPI MARKET SEGMENTATION  
FIGURE 15 NORTH AMERICA: PORTER’S FIVE FORCES  
FIGURE 16 EUROPE: PORTER’S FIVE FORCES  
FIGURE 17 ASIA: PORTER’S FIVE FORCES  
FIGURE 18 KEY GROWTH STRATEGIES,  2011 - 2016

The pharmaceutical API manufacturing industry is undergoing a period of rapid change due to multiple factors such as patent expiry of the top selling pharmaceuticals, the ever changing nature of the drugs being manufactured, and the surge in API manufacturing from the emerging regions.

On the basis of route of synthesis, the global API market can be divided into two broad categories: synthetic chemicals API and biopharmaceuticals API.

The evolution of synthetic chemical processing and R&D has brought many important therapeutic products such as Penicillin to the world markets. Currently, the API market is dominated by synthetic chemicals API. The contribution of biopharmaceutical API towards the global API market is considerably lesser as compared to synthetic chemicals as these are a relatively new trend in the market. However, with the growth of the biotechnology industry worldwide, the use of biotech derived molecules is spurring growth in the API market.

The increasing complexity of diseases also favors the growing demand of biotech drugs. Hence, the share of biotech APIs will increase significantly in the coming years and will drive the overall market of APIs. In the future, biopharmaceutical APIs provide a promising outlook and are expected to surpass the growth rates for synthetic API.

The global API market is poised at $108.77 billion in 2011, growing and is expected to grow at a steady CAGR till 2016.

The global pharmaceutical market was hit hard by the economic recession, and as a result, cost containment was the major agenda of all the governments across the globe. With government leaders being forced to make difficult choices pertaining to healthcare spending, the use of generics has been promoted, resulting in an inadvertent increase of the Generics market.

European countries such as the U.K., France, and Germany are promoting the use of Generics by providing incentives to the doctors for writing prescriptions for generic drugs and also to the pharmacists if they offer the generic equivalent of prescribed drugs.

Due to the huge competition faced by API manufacturers, along with the erosion of the drug pricing, the API players have moved to providing value added services and hence are venturing into Biosimilars and HPAPI market, which provides huge opportunities

Market Attractiveness, by Country, 2010

Source: MarketsandMarkets analysis

The U.S. is the largest market for API; followed by Japan and Germany in 2010. These countries are leading the API market in terms of value. The U.S. has the largest market for the Innovative Biotech Market in the world. However, market for generics is still very niche as compared to the Asian countries. Similarly, Japan is second leader after the U.S. for the Innovative Drug Market. The countries having high ranking for the year 2010 are U.S., Japan; followed by Germany and France.

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports